BIIB Stock Price Today (September 2026) — Biogen Inc. Analysis & Key Metrics 2026-09-03
Biogen Inc. (BIIB) is trading at $224.51, up 0.83% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $236.22 (5.2% upside).
- Volatility remains elevated (24.22% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (3.40% YoY) alongside significant competitive pressures.
BIIB Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Biogen Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $39.35B
P/E Ratio
Forward P/E: 13.10
Revenue Growth
Year over Year
Analyst Target
+5.2% upside potential
Key Investor Questions About BIIB
What investors need to know before buying
Based on current market data, BIIB presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 66.40)
- Fundamentals say: Caution warranted (high leverage concerns)
BIIB's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for BIIB investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $8.36B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, BIIB stock traded between $133.53 and $222.85—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 24.22% annualized volatility and β=0.59, the stock exhibits low sensitivity to market moves—making BIIB suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Why Is Veeva Systems (VEEV) Winning Big In AI For Biopharma?
Veeva Systems (NYSE: VEEV) announced that Regeneron and Biogen have adopted its AI powered Vault CRM suite globally. The company also introduced Veeva Falcon Safety, a new agentic safety operations product for biopharma clients. Both moves expand Veeva Systems' AI focused offering across commercial and safety workflows in life sciences. These updates highlight how AI heavy software is becoming core infrastructure for healthcare and biopharma workflows. This connects directly to a wider set...
Biogen (BIIB) Brings At Home Weekly Alzheimer’s Injection To U.S. Patients
Biogen (NasdaqGS: BIIB) and Eisai launched LEQEMBI IQLIK, a once-weekly subcutaneous injection for early Alzheimer's disease, now available in the U.S. for initiation and maintenance therapy. The treatment allows at-home dosing for eligible patients using a pre-filled syringe or autoinjector, following a step-up initiation schedule. LEQEMBI IQLIK is described as the first anti-amyloid therapy with an approved subcutaneous initiation option that can be started outside an infusion...
Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data
Biogen stock has delivered a strong 57.2% return over the past year, yet investors are faced with a split verdict on value as a Discounted Cash Flow (DCF) intrinsic value estimate points to a large discount while earnings based multiples screen the shares as expensive. The result is a low overall value score that conflicts with what the DCF suggests. Over the latest 1 year window, Biogen has returned 57.2%, which puts recent share price momentum firmly ahead of its longer term track...
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biogen’s (BIIB) Immunology Bet Meets A Pricier Balance Sheet
On August 6, Biogen (NASDAQ:BIIB) completed its acquisition of RayThera, a privately held biotech developing small-molecule immunology therapies whose lead program entered Phase 1 trials in July 2026. The deal lands just over a week after the company posted a second-quarter beat that sent shares up nearly 5% on July 29. Together, the two moments […]
Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks
In a recent interview on CNBC’s Halftime Report, Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte (NASDAQ: INCY) and Biogen (NASDAQ: BIIB) as two of his “Best Stocks in the Market.” Brown said he wanted to focus on stocks that had “nothing to do” with the AI and data-center spending theme. “We wanted to […]
Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report?
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Veeva Systems Inc (VEEV) (Q2 2027) Earnings Call Highlights: Record CRM Quarter and AI Momentum ...
Veeva Systems Inc (VEEV) reports $928 million in revenue and best-ever CRM performance, with Veeva Falcon AI gaining traction.
Veeva Systems Q2 Earnings Call Highlights
Veeva Systems (NYSE:VEEV) reported fiscal 2027 second-quarter revenue of $928 million and non-GAAP operating income of $416 million, with Chief Executive Officer Peter Gassner saying results exceeded the company’s guidance. Management highlighted record CRM performance, broad commercial-cloud moment
Veeva's Vault CRM Wins Reinforce Market-Leader Status Ahead of Earnings, Truist Says
Veeva Systems' (VEEV) Vault CRM has cemented its position as the clear market leader in life science
Explore More Analysis for BIIB
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Biogen Inc.
Biogen Inc. (BIIB) is currently trading at $224.51. The RSI (14-day) is at 66.4, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $236.22 implies 5.2% upside from current levels. Volatility is moderate at 24.2% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Biogen Inc. (BIIB): The trailing P/E ratio is 40.16, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 13.10, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.56, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 1.76. Price-to-Sales is 3.31. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 31 analysts covering BIIB, the consensus price target is $236.22. This represents a 5.2% upside from the current price of $224.51. The range spans from a low target of $165.00 to a high target of $300.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Biogen Inc. (BIIB) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Biogen Inc. (BIIB) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Biogen Inc.'s (BIIB) current debt and financial health profile: Total debt stands at $8.36B. The debt-to-equity ratio is 44.33, which is moderate and generally manageable for most companies. The current ratio is 1.86, indicating strong short-term liquidity. The quick ratio is 0.94. The company holds $1.28B in cash and equivalents. Free cash flow is positive at $1.27B, providing a cushion for debt servicing and shareholder returns.